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Abstract Caffeine is the most widely used behaviorally active
drug in the world which exerts its activity on central nervous
system through adenosine receptors. Worrying data indicate
that excessive caffeine intake applies to patients suffering from
mental disorders, including depression. The main goal of the
present study was to evaluate the influence of caffeine on ani-
mals’ behavior in forced swim test (FST) as well as the effect of
caffeine (5 mg/kg) on the activity of six typical antidepressants,
such as imipramine (15 mg/kg), desipramine (10 mg/kg), flu-
oxetine (5 mg/kg), paroxetine (0.5 mg/kg), escitalopram
(2 mg/kg), and reboxetine (2.5 mg/kg). Locomotor activity
was estimated to verify and exclude false-positive/negative re-
sults. In order to assess the influence of caffeine on the levels of
antidepressant drugs studied, their concentrations were deter-
mined in murine serum and brains using high-performance
liquid chromatography. The results showed that caffeine at a
dose of 10, 20, and 50 mg/kg exhibited antidepressant activity
in the FST, and it was not related to changes in locomotor
activity in the animals. Caffeine at a dose of 5 mg/kg potenti-
ated the activity of all antidepressants, and the observed effects
were not due to the increase in locomotor activity in the ani-
mals. The interactions between caffeine and desipramine, flu-
oxetine, escitalopram, and reboxetine were exclusively of phar-
macodynamic character, because caffeine did not cause any
changes in the concentrations of these drugs neither in blood
serum nor in brain tissue. As a result of joint administration of
caffeine and paroxetine, an increase in the antidepressant drug
concentrations in serum was observed. No such change was
noticed in the brain tissue. A decrease in the antidepressant drug
concentrations in brain was observed in the case of imipramine
administered together with caffeine. Therefore, it can be as-
sumed that the interactions caffeine-paroxetine and caffeine-
imipramine occur at least in part in the pharmacokinetic phase.
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Introduction
Caffeine is one of the most frequently used psychoactive sub-
stances ingested mainly via food products (Fredholm et al.
1999). What is more, it is applied for therapeutic purposes
when combined with analgesics (Andrews et al. 2007;
Shapiro 2007) and antihistamines or in dietary supplements
for weight loss (Andrews et al. 2007; Barone and Roberts
1996; Burke 2008; Shapiro 2007). Caffeine exhibits a stimulat-
ing activity which facilitates physical and mental tiredness and
helps to improve thinking process (Nehlig et al. 1992). Caffeine
consumption rises every year. Worrying data indicate that ex-
cessive caffeine intake applies to patients suffering frommental
disorders (≥750 mg caffeine daily) (Rihs et al. 1996).
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After oral administration, caffeine is absorbed from the
gastrointestinal tract into the bloodstream in 99 % (Fredholm
et al. 1999). The highest concentration of caffeine in plasma is
reached 30–60 min after ingestion. Caffeine easily penetrates
the intracellular space. It is distributed to all body fluids, that
is, plasma, cerebrospinal fluid, saliva, bile, semen, milk, um-
bilical cord blood, and organ tissues (Arnaud 2011).
Hydrophobic properties of caffeine allow its easy penetration
through all biological membranes. The blood-brain barrier
does not prevent caffeine (Lorist and Tops 2003). As the frac-
tion bound to plasma proteins is low, almost all of caffeine in
blood is present in a pharmacologically active form (Arnaud
2011; Lorist and Tops 2003). The main enzyme responsible
for the metabolism of caffeine is the isoenzyme CYP1A2 of
cytochrome P450 (Carrillo and Benitez 2000).
Caffeine is not accepted as a standard pharmacological
treatment of mood disorders, but it is likely that some people
can use it as an antidepressant drug in the early stages of this
disease (Casas et al. 2004). It is thus possible to demonstrate
the usefulness of caffeine and its derivatives in the treatment
of depression. It has been shown that caffeine can reverse the
monoaminergic system changes observed in depression, for
example, caffeine blocking the A1 adenosine receptor subunit
may increase the levels of catecholamines and serotonin (5-
HT) in the central nervous system (CNS) (Fredholm 1995).
What seems to be important is the fact that caffeine contributes
to an increased 5-HT release in the limbic areas and the release
of dopamine (DA) in the prefrontal cortex, which is compara-
ble to the effect obtained with the use of antidepressants
(Acquas et al. 2002; Fredholm 1995).
Caffeine exerts its activity on CNS through adenosine re-
ceptors for which it acts as an antagonist (Benowitz 1990;
Dunwiddie and Masino 2001; Fredholm et al. 1999;
Pettenuzzo et al. 2008). It was found in various studies, both
in vitro and in vivo, that caffeine affects the activity of endog-
enous adenosine inhibiting the release of various neurotrans-
mitters in CNS: acetylcholine, γ-aminobutyric acid (GABA),
glutamate, DA, noradrenaline (NA), and 5-HT (El Yacoubi
et al. 2003; El Yacoubi et al. 2001; Ferré et al. 1996a; Ferré
et al. 1996b; Fisone et al. 2004; Williams 1987).
World Health Organization (WHO) estimated that currently,
there are 350 million people around the world suffering from
depressive disorders. WHO predictions indicate that by 2020,
depression will be the second of civilization disease causing
incapacity. Moreover, the age in which the first symptoms of
depressive disorders appear is substantially reduced each year.
Due to an increasing number of cases diagnosed with mental
illnesses, including depression, interactions between caffeine
and other drugs used in pharmacotherapy of these disorders
attract more and more attention. The main goal of this study
was to assess the effect of caffeine on animals’ behavior in the
forced swim test (FST), which is a widely used behavioral test
in estimating antidepressant properties of drugs. Moreover, we
also decided to evaluate the influence of caffeine on the activity
of typical antidepressant drugs, i.e., imipramine, and its metab-
olite desipramine—the tricyclic antidepressants (TCAs)—flu-
oxetine, escitalopram, and paroxetine—the selective serotonin
reuptake inhibitors (SSRIs)—and reboxetine—a selective nor-
adrenaline reuptake inhibitor (SNRI).
Material and methods
Animals
The experiment was carried out on naïve adult male Albino
Swiss mice (25–30 g) purchased from the licensed breeder
(Kolacz, Warsaw, Poland). The animals were housed in the
environmentally controlled rooms with a 12-h light/dark cy-
cle, in groups of 10 in standard cages under strictly controlled
laboratory conditions—temperature maintained at 21–23 °C
and relative humidity about 45–55 %. Throughout the study,
the animals were given ad libitum access to water and food.
The experiment began after at least 1-week acclimation period
in the laboratory conditions and was conducted between 8
a.m. and 3 p.m. to minimize circadian influences. Each exper-
imental group consisted of 7–10 animals. All procedures were
conducted in accordance with the European Communities
Council Directive of 22 September 2010 (2010/63/EU) and
Polish legislation acts concerning animal experimentations.
The experimental procedures and protocols were approved
by the First Local Ethics Committee at the Medical
University of Lublin. Each mouse was used only once.
Drugs
Caffeine (1,3,7-trimethylxanthine; 5, 10, 20, and 50 mg/kg,
Sigma-Aldrich, Poznań, Poland), imipramine hydrochloride
(15 and 30 mg/kg, Sigma-Aldrich), desipramine hydrochlo-
ride (10 mg/kg, Sigma-Aldrich), fluoxetine hydrochloride
(5 mg/kg, Sigma-Aldrich), escitalopram oxalate (2 mg/kg,
Sigma-Aldrich), paroxetine hydrochloride (0.5 mg/kg,
Abcam Biochemicals, Cambridge, UK), and reboxetine mes-
ylate (2.5 mg/kg, Abcam Biochemicals) were dissolved in
0.9 % NaCl. The solutions of antidepressants were adminis-
tered intraperitoneally (i.p.) 60 min before behavioral testing,
whereas caffeine solution was administered i.p. 40 min before
the tests. The doses and pretreatment schedules were selected
on those reported in the literature and on the basis of the
results of our previous experiments (David et al. 2003;
Poleszak et al. 2006; Szewczyk et al. 2002; Szewczyk et al.
2009; Urani et al. 2001). All solutions were prepared imme-
diately prior to the experiment. Animals from the control
groups received i.p. injections of the vehicle (0.9 % saline).
The volume of the vehicle or drug solutions for i.p. adminis-
tration was 10 ml/kg.
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Forced swim test
The procedure was carried out onmice, according to the meth-
od of Porsolt et al. (1977). Each mouse was placed individu-
ally into the glass cylinders (height 25 cm, diameter 10 cm)
containing 10 cm of water at 23–25 °C. The animals were left
in the cylinder for 6 min. The total duration of immobility was
recorded by cumulative stopwatches during the last 4 min of
the 6-min-long testing period. The mouse was judged to be
immobile when it ceased struggling and remained floating
motionless in the water, making only the movements neces-
sary to keep its head above the water level.
The results obtained in the forced swim test were shown as
the arithmetic mean of immobility time of animals in seconds±
standard error of the mean (SEM) for each experimental group.
Spontaneous locomotor activity
In order to avoid the risk of obtaining the false-positive/nega-
tive effects in the FSTcaused by a possible influence of tested
agents on the locomotor activity, the spontaneous locomotor
activity was measured using an animal activity meter Opto-
Varimex-4 Auto-Track (Columbus Instruments, USA). This
actimeter consisted of four transparent cages with a lid (43×
43×32 cm), a set of four infrared emitters (each emitter has 16
laser beams), and four detectors monitoring animal move-
ments. After i.p. pretreatment with respective drugs or drug
combinations (antidepressants and saline were administered
i.p. 60 min, and caffeine i.p. 40min before the test), mice were
placed individually into the cages for 10 min. Spontaneous
locomotor activity was evaluated between the second and
the sixth minute, which corresponds with the time interval
analyzed in the FST.
The results obtained in this test were presented as the arith-
metic average distance that a mouse traveled (in centimeters)±
SEM for each experimental group.
Determination of antidepressants in serum and brain
tissue
Sixty minutes following administration of the antidepressant
drugs with or without caffeine, mice were decapitated to col-
lect biological material for pharmacokinetic studies. The
blood was collected into Eppendorf tubes and allowed to clot
at room temperature. Subsequently, the blood was centrifuged
at 10,000 rpm for 10 min and serum was collected into poly-
ethylene tubes and frozen at −25 °C. Immediately after the
decapitation, the brains were dissected from the skull, washed
with 0.9 % NaCl, and also frozen at −25 °C.
Serum and brain concentrations of the studied antide-
pressants were assayed by a high-performance liquid
chromatography (HPLC) method. The brains were ho-
mogenized in distilled water (1:4, w/v) with a tissue
homogenizer TH220 (Omni Inte rnat ional , Inc . ,
Warrenton, VA, USA). For all studied drugs, the extrac-
tion from serum and brain homogenates was performed
using the mixture of ethyl acetate/hexane (30:70, v/v).
The only exceptions were paroxetine and reboxetine, for
which the solvents were mixed at a 50:50 (v/v) ratio.
Amitriptyline (2 μg/ml) was used as an internal standard
(IS) for desipramine and imipramine, desipramine
(500 ng/ml) for paroxetine and reboxetine, and paroxetine
(200 ng/ml) for fluoxetine and escitalopram. In order to
isolate imipramine and desipramine, to serum (200 μl)
and brain homogenate (0.5 ml) containing these drugs,
the IS was added and the samples were alkalized with
100 and 250 μl of 4 M NaOH, respectively. Then, the
samples were extracted with 5 ml of the extraction reagent
by shaking for 20 min (IKA Vibrax VXR, Germany).
After centrifugation at 3000 rpm for 20 min (Universal
32, Hettich, Germany), the organic layer was transferred
to a new tube containing a 200 μl solution of 0.1 M
H2SO4 and methanol (90:10, v/v), shaken for 0.5 h and
then centrifuged for 15 min (3000 rpm). A 50-μl aliquot
of this solution was injected into the HPLC system. In the
case of escitalopram, the procedure was similar with the
exception that the extraction with an organic reagent
(3 ml) was repeated two times, 1 ml of brain homogenate
was used, and the volume of the acidic phase was 100 μl.
Fluoxetine, paroxetine, and reboxetine were extracted
from 200 μl of serum after addition of the appropriate
IS, 100 μl of 4 M NaOH, and 3 ml of the extraction
reagent. The procedure was repeated twice. In turn, to
1 ml of brain homogenates containing these drugs, the
IS was added and the samples were alkalized with
500 μl of 4 M NaOH. After the addition of 1 ml of the
concentrated NaCl solution (10 g/50 ml), the samples were
vortexed for 15 s and 5ml of the extraction reagent was added.
Then, serum samples and brain homogenates were shaken for
20 min and centrifuged for 15 min at 3000 rpm. After the
centrifugation, the organic layer was transferred into a conical
glass tube and evaporated to dryness at 37 °C under a gentle
stream of nitrogen in a water bath. The residue was dissolved
with 100 μl of methanol, and 50 μl of this solution was
injected into the HPLC system.
The HPLC system (Thermo Separation Products, San Jose,
CA, USA) consisted of a P100 isocratic pump, a UV100
variable-wavelength UV/VIS detector, a Rheodyne 7125 in-
jector (Rheodyne, Cotati, CA, USA) with a 50-μl sample
loop, and a Chromjet SP4400 computing integrator.
All analyses were performed on a 250 × 4 mm
LiChrospher®100 RP-18 column with a particle size of 5 μm
(Merck, Darmstadt, Germany) protected with a guard column
(4×4 mm) with the same packing material. The mobile phase
consisting of acetonitrile and 50 mM potassium dihydrogen
phosphate was mixed at a ratio of 60:40 (v/v) for imipramine,
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desipramine, and fluoxetine and 65:35 (v/v) for escitalopram,
paroxetine, and reboxetine and run at 1 ml/min.
Chromatographic analysis was carried out at 21 °C, and the
analytical wavelength of 227 nm for fluoxetine, 240 nm for
escitalopram, and 214 nm for the remaining antidepressants
studied.
The calibration curves constructed by plotting the ratio of
the peak heights of the studied drug to IS versus concentration
of the drug were linear in the tested concentration ranges. No
interfering peaks were observed in the chromatograms. The
assays were reproducible with low intra- and inter-day varia-
tion (coefficient of variation less than 10 %). The extraction
efficiencies of the analyzed compounds and internal standards
ranged from 66 to 97 %. Antidepressant concentrations were
expressed in nanograms per milliliter of serum or nanograms
per gram of wet brain tissue.
Statistical analysis
The statistical analysis of the results obtained in the FST and
the locomotor activity assessment following caffeine admin-
istration was carried out using one-way ANOVA with
Dunnett’s post hoc test and after joint treatments using two-
way ANOVA with Bonferroni’s post hoc test. Interactions
occurring between tested agents were analyzed with one-
way ANOVA also with Bonferroni’s post hoc test. The con-
centrations of the tested antidepressant drugs in blood and
brains of mice in the presence and absence of caffeine were
compared using Student’s t test. p values less than or equal to
0.05 were considered statistically significant.
Results
Caffeine dose-effect relationship in the FST
In order to determine its antidepressant activity, caffeine was
used in the following doses: 5, 10, 20, and 50 mg/kg (Fig. 1)
[one-way ANOVA: F(5,55)=8.536; p<0.0001]. Statistical anal-
ysis of the results showed that caffeine used at a dose of 5 mg/kg
had no statistically significant effect (p>0.05) on the reduction
of the immobility time in mice. However, caffeine administered
at a dose of 10, 20, and 50 mg/kg significantly reduced the total
time of immobility in comparison with the control group.
The influence of caffeine on the antidepressant activity
of tested drugs in the FST
Effect of combined administration of caffeine and imipramine
in the FST
The effect of the combined administration of caffeine and
imipramine on the total duration of the immobility time in
mice is shown in Fig. 2a. Caffeine (5 mg/kg) injected in com-
binationwith imipramine (15 mg/kg) significantly reduced the
immobility time in the FST in mice (Fig. 2a). We carried out
analysis using two-way ANOVA followed by one-way
ANOVAwith Bonferroni’s post hoc test.
Two-way ANOVA demonstrated an interaction between
imipramine and caffeine [F(1,28)=24.86, p<0.0001]. One-
way ANOVAs followed by Bonferroni’s post hoc test showed
no effect of caffeine (p>0.05) and no effect of imipramine
(p>0.05) alone. However, the effect of imipramine became
significant in the presence of caffeine (p<0.0001).
Effect of combined administration of caffeine
and desipramine in the FST
The effect of the combined administration of caffeine and
desipramine on the total duration of the immobility time in
mice is shown in Fig. 2b. Caffeine (5 mg/kg) injected in com-
bination with desipramine (10 mg/kg) significantly reduced
the immobility time in the FST in mice (Fig. 2b). We carried
out analysis using two-way ANOVA followed by one-way
ANOVAwith Bonferroni’s post hoc test.
Two-way ANOVA demonstrated an interaction between
desipramine and caffeine [F(1,35)=9.06, p<0.0048]. One-
way ANOVAs followed by Bonferroni’s post hoc test showed
no effect of caffeine (p>0.05) and no effect of desipramine
(p>0.05) alone. However, the effect of desipramine became
significant in the presence of caffeine (p<0.0001).
Effect of combined administration of caffeine and fluoxetine
in the FST
The effect of the combined administration of caffeine and
fluoxetine on the total duration of the immobility time in mice
is shown in Fig. 2c. Caffeine (5 mg/kg) injected in
Fig. 1 The antidepressant activity of caffeine in the forced swim test in
mice. Caffeine and saline were administered i.p. 40 min, and imipramine
i.p. 60 min before the test. The data are presented as the means±SEM.
Each experimental group consisted of 10 animals. *p<0.05, ***p<0.001
(one-way ANOVA followed by Dunnett’s post hoc test)
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combination with fluoxetine (5 mg/kg) significantly reduced
the immobility time in the FST in mice (Fig. 2c). We carried
out analysis using two-way ANOVA followed by one-way
ANOVAwith Bonferroni’s post hoc test.
Two-way ANOVA demonstrated an interaction between
fluoxetine and caffeine [F(1,28)=29.10, p<0.0001]. One-
way ANOVAs followed by Bonferroni’s post hoc test showed
no effect of caffeine (p>0.05) and no effect of fluoxetine
(p>0.05) alone. However, the effect of fluoxetine became
significant in the presence of caffeine (p<0.0001).
Effect of combined administration of caffeine and paroxetine
in the FST
The effect of the combined administration of caffeine and
paroxetine on the total duration of the immobility time in mice
is shown in Fig. 2d. Two-way ANOVA demonstrated a lack of
interaction between paroxetine and caffeine [F(1,36)=3.45,
p=0.0716], but a significant effect of paroxetine [F(1,36)=
18.43, p=0.0001] and a significant effect of caffeine [F(1,
36)=13.07, p=0.0009].
Effect of combined administration of caffeine
and escitalopram in the FST
The effect of the combined administration of caffeine and
escitalopram on the total duration of the immobility time in
mice is shown in Fig. 2e. Caffeine (5 mg/kg) injected in com-
bination with escitalopram (2mg/kg) significantly reduced the
immobility time in the FST in mice (Fig. 2e). We carried out
analysis using two-way ANOVA followed by one-way
ANOVAwith Bonferroni’s post hoc test.
Two-way ANOVA demonstrated an interaction between
escitalopram and caffeine [F(1,36)=5.88, p=0.0204]. One-
way ANOVAs followed by Bonferroni’s post hoc test showed
no effect of caffeine (p>0.05) and no effect of escitalopram
(p>0.05) alone. However, the effect of escitalopram became
significant in the presence of caffeine (p<0.0001).
Fig. 2 Effect of combined
administration of caffeine and
antidepressants in the forced
swim test in mice. Caffeine was
administered i.p. 40 min, and all
antidepressants and saline were
administered i.p. 60 min before




Bonferroni’s post hoc test). The
control groups for imipramine
and fluoxetine as well as
desipramine and paroxetine are
the same
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Effect of combined administration of caffeine and reboxetine
in the FST
The effect of the combined administration of caffeine and
reboxetine on the total duration of the immobility time in mice
is shown in Fig. 2f. Caffeine (5 mg/kg) injected in combina-
tion with reboxetine (2.5 mg/kg) significantly reduced the
immobility time in the FST in mice (Fig. 2f). We carried out
analysis using two-way ANOVA followed by one-way
ANOVAwith Bonferroni’s post hoc test.
Two-way ANOVA demonstrated an interaction between
reboxetine and caffeine [F(1,35)=6.96, p=0.0124]. One-way
ANOVAs followed by Bonferroni’s post hoc test showed no
effect of caffeine (p>0.05) and no effect of reboxetine
(p>0.05) alone. However, the effect of reboxetine became
significant in the presence of caffeine (p<0.0001).
Effect of caffeine on locomotor activity in mice
The effect of caffeine (5, 10, 20, and 50 mg/kg) on spontane-
ous locomotor activity in mice is shown in Table 1 [one-way
ANOVA, F(4,35)=0.7440, p=0.5686]. Statistical analysis of
the results showed that caffeine used in all tested doses had no
statistically significant effect on locomotor activity in mice
versus control group.
Effect of combined administration of caffeine
and antidepressants on locomotor activity in mice
The effect of the combined administration of caffeine and
tested antidepressant drugs on spontaneous locomotor ac-
tivity in mice is shown in Table 2. Caffeine or antidepres-
sants (imipramine, fluoxetine, paroxetine, reboxetine, and
escitalopram) administered either alone or combined to-
gether had no statistically significant effects on the loco-
motor activity in mice (Table 2). Desipramine adminis-
tered alone had no significant effects on the locomotor
activity in mice, while co-administered with caffeine
decreased the locomotor activity in mice in comparison
with the control and caffeine-treated group [one-way
ANOVA, F(3,28)=7.309, p<0.001 and p<0.01, respec-
tively] (Table 2).
Two-way ANOVA demonstrated:
(A) No effect of imipramine [F(1,25)=1.19, p=0.2857], no
effect of caffeine [F(1,25)=0.11, p=0.7450], and no in-
teraction [F(1,25)=0.64, p=0.4312].
(B) Extremely significant effect of desipramine [F(1,28)=
19.02, p=0.0002], no effect of caffeine [F(1,28)=1.79,
p=0.1914], and no interaction [F(1,28)=1.11, p=0.3011].
(C) No effect of fluoxetine [F(1,26)=0.05, p=0.8237], no
effect of caffeine [F(1,26)=0.10, p=0.7527], and no in-
teraction [F(1,26)=0.01, p=0.9342].
(D) No effect of paroxetine [F(1,28)=0.13, p=0.7241], no
quite significant effect of caffeine [F(1,28)=3.63, p=
0.0672], and no interaction [F(1,28)=0.05, p=0.8209].
(E) No effect of escitalopram [F(1,28)=0.65, p=0.4271], no
effect of caffeine [F(1,28)=1.25, p=0.2726], and no in-
teraction [F(1,28)=1.1, p=0.3231].
Table 1 Effect of caffeine on locomotor activity in mice
Treatment (mg/kg) Distance traveled (cm)





Caffeine and salinewere administered i.p. 40min before the test. Distance
traveled was recorded between the second and the sixth minute of the test.
The data are presented as the means±SEM. Each experimental group
consisted of 7–8 animals. The results were considered statistically signif-
icant if p<0.05 (one-way ANOVA followed by Dunnett’s post hoc test)
Table 2 Effect of treatments on spontaneous locomotor activity inmice




Caffeine 5+imipramine 15 558.6±48.21
Fluoxetine 5+saline 628.4±64.80




Caffeine 5+desipramine 10 539.8±31.14 ^^
Paroxetine 0.5+saline 759.0±97.15








Caffeine 5+reboxetine 2.5 696.0±68.45
Antidepressants and saline were administered i.p. 60 min, and caffeine
i.p. 40 min before the experiment. Distance traveled was recorded be-
tween the second and the sixth minute of the test. Each experimental
group consisted of 7–8 animals. Data are presented as the means±SEM
^^p<0.01 versus caffeine-treated group (two-way ANOVA followed by
Bonferroni’s post hoc test)
216 Naunyn-Schmiedeberg's Arch Pharmacol (2016) 389:211–221
(F) Very significant effect of reboxetine [F(1,23)=9.95, p=
0.0044], not quite significant effect of caffeine [F(1,
23)=3.23, p=0.0857], and no interaction [F(1,23)=
0.00, p=0.9612].
Pharmacokinetic studies
The effect of caffeine on serum and brain concentrations of the
tested antidepressants in mice is shown in Tables 3 and 4. Only
in the case of co-administration of caffeine and paroxetine an
increased paroxetine concentration in serum was observed (t
test, p=0.0296) without affecting its concentration in the brain
tissue. Conversely, caffeine lowered the concentration of imip-
ramine in brain tissue (t test, p=0.0207) with no significant
effect on its concentration in serum (Tables 3 and 4).
Discussion
Caffeine is one of the most commonly used psychoactive sub-
stances in the world (Solinas et al. 2002). Products containing
caffeine have gained popularity due to the stimulant effect on
the CNS. An excessive intake of caffeine is particularly prev-
alent amongst the patients hospitalized due to mental disor-
ders. It is estimated that as many as 22 % of these people
consumed more than 750 mg caffeine a day, whereas such a
high intake of this methylxanthine was found in 9 % of the
general population (Hughes et al. 1998). Caffeine acts on the
CNS both directly and indirectly. In non-toxic doses, caffeine
acts mainly as an antagonist of adenosine inhibitory A1 and
stimulatory A2A receptors and these receptors control the neu-
ronal excitability and the release of several neurotransmitters,
including ACh, DA, NA, and 5-HT. Only in higher doses
caffeine is capable to inhibit the activity of phosphodiesterases
and GABA receptors or mobilize intracellular Ca2+ (Fredholm
1995; Goldberg et al. 1982; Lorist and Tops 2003; Williams
1987).
Numerous animal studies indicate that psychostimulant-
active compounds such as caffeine or amphetamine reduce
the duration of immobility time in the FST (Enríquez-
Castillo et al. 2008; Gan et al. 2009; Vieira et al. 2008), and
the observed effect is comparable with the one recorded after
administration of tricyclic antidepressants (i.e., imipramine,
desipramine), SSRIs (i.e., fluoxetine, paroxetine, or sertra-
line), and SNRIs (Page et al. 1999). Other adenosine receptor
antagonists, e.g., istradefylline (KW 6002) (El Yacoubi et al.
2003; El Yacoubi et al. 2001; Yamada et al. 2013), and SCH
58261 (El Yacoubi et al. 2003; El Yacoubi et al. 2001) exerted
an antidepressant-like activity in the FST and the tail suspen-
sion test (TST), as well.
However, according to the literature (Batalha et al. 2013;
Pechlivanova et al. 2012) (Lucas et al. 2011; Smith 2002), caf-
feine affects mood of animals and humans in a dose-dependent
manner. A low dose of this methylxanthine (10 mg/kg) reduces
the duration of immobility time of rodents in the FST, while its
high dose (100 mg/kg) produces the opposite effect (Gan et al.
Table 3 Effect of caffeine on the concentrations of antidepressants in
mouse serum
Treatment Drug concentration (ng/ml)
(A) Imipramine 15+saline 352.4±72.13
(Metabolite–desipramine) (34.69±6.17)
Imipramine 15+caffeine 5 213.8±31.27
(Metabolite–desipramine) (43.92±11.83)
(B) Desipramine 10+saline 203.7±22.54
Desipramine 10+caffeine 5 220.6±25.05
(C) Fluoxetine 5+saline 404.5±41.65
Fluoxetine 5+caffeine 5 435.0±36.87
(D) Paroxetine 0.5+saline 35.7±5.68
Paroxetine 0.5+caffeine 5 63.9±10.50*
(E) Escitalopram 2+saline 81.1±3.40
Escitalopram 2+caffeine 5 86.4±5.15
(F) Reboxetine 2.5+saline 211.0±23.05
Reboxetine 2.5+caffeine 5 160.4±15.42
Antidepressants were administered i.p. 60 min, and caffeine 40 min be-
fore decapitation. Each experimental group consisted of 9–10 animals.
Results are presented as mean values±SEM
*p<0.05 compared to the respective control group (Student’s t test)
Table 4 Effect of caffeine on the concentrations of antidepressants in
mouse brain
Treatment Drug concentration (ng/g)
(A) Imipramine 15+saline 5022.0±749.90
(Metabolite–desipramine) (433.0±100.10)
Imipramine 15+caffeine 5 2920.0±354.00*
(Metabolite–desipramine) (320.0±62.09)
(B) Desipramine 10+saline 2100.0±201.30
Desipramine+caffeine 5 2455.0±259.40
(C) Fluoxetine 5+saline 6091.0±484.90
Fluoxetine 5+caffeine 5 6915.0±268.10
(D) Paroxetine 0.5+saline 129.5±9.78
Paroxetine 0.5+caffeine 5 144.8±15.92
(E) Escitalopram 2+saline 372.5±29.12
Escitalopram 2+caffeine 5 371.2±31.17
(F) Reboxetine 2.5+saline 411.7±31.94
Reboxetine 2.5+caffeine 5 378.8±34.06
Antidepressants were administered i.p. 60 min, and caffeine 40 min be-
fore decapitation. Each experimental group consisted of 10 animals. Re-
sults are presented as mean values±SEM
*p<0.05 compared to the respective control group (Student’s t test)
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2009). Also, El Yacoubi et al. showed that caffeine at stimulant
doses was effective in FST (El Yacoubi et al. 2003). It is be-
lieved that the influence on catecholamines and 5-HT neuro-
transmission is responsible for the response observed after ad-
ministration of the low dose of caffeine (Rénéric and Lucki
1998). An injection of the higher dose is probably related to
an excessive increase in the level of ACh and 5-HT in the
CNS, which leads to the inhibition of adenosine receptors
(Nikodijević et al. 1993a; Nikodijević et al. 1993b). What is
more, in their most recent research, Kaster et al. showed protec-
tive effects of caffeine on maladaptive changes in the model of
chronic unpredictable stress, which was comparable with the
selective blocking of adenosine A2A receptors. This study point-
ed out that adenosine A2A receptor blockers have therapeutic
benefits and their use should be considered as a novel therapy
to counteract the negative impact of chronic stress on mood
(Kaster et al. 2015). The results of our study confirmed the
antidepressant-like activity of caffeine given at the doses of 10,
20, and 50 mg/kg. Moreover, the highest dose used by us
exerted an effect similar to the action of imipramine adminis-
tered at an active dose (30 mg/kg).
We also demonstrated that caffeine may affect the ac-
tion of typical antidepressant drugs, such as imipramine,
desipramine, fluoxetine, escitalopram, paroxetine, and
reboxetine. Co-administration of caffeine with these
agents at the non-active doses resulted in a statistically
significant reduction in the immobility times in the FST
compared with the control groups. It should be noted that
the observed effects were not due to the increase in loco-
motor activity of animals. Most probably, the shorter im-
mobility time noted after the joint administration of caf-
feine and imipramine or desipramine may be a conse-
quence of the enhancement of NA and 5-HT transduction
(Lorden and Nunn 1982). Caffeine influences A1 recep-
tors, which are located on serotonergic neurons in the dor-
sal nucleus structures (Mössner et al. 2000) and in the
locus coeruleus (Regenold and Illes 1990). It is known that
the stimulation by endogenous adenosine or adenosine se-
lective agonists causes a reduction in the activity of sero-
tonergic neurons (Regenold and Illes 1990), which leads
to a decrease in the adrenergic and serotonergic transmis-
sion (Okada et al. 2002). Caffeine through antagonism of
the A1 receptors, inter alia, blocks the effects of endoge-
nous adenosine and increases NA and 5-HT transduction
in the CNS (Fredholm et al. 1999; Kulkarni and Mehta
1985; Schlosberg 1984), which may explain the synergis-
tic effect on the performance of the tested TCAs. Another
cause of the synergistic effect of caffeine and imipramine
or desipramine may be an impaired metabolism of caffeine
by these antidepressants. It has been shown that both imip-
ramine and desipramine inhibit the demethylation and hy-
droxylation of caffeine which reduces the elimination of
caffeine from the organism (Daniel et al. 2003). In the
research published by Robles-Molina (2012), the concur-
rent administration of caffeine and desipramine did not
change the locomotor activity of animals, while we no-
ticed their hypolocomotion. However, such a discrepancy
might arise due to the application of different doses of the
tested substances (0.31, 1 mg/kg of caffeine and 0.31, 1,
3.1 mg/kg of desipramine versus 5 mg/kg of caffeine and
10 mg/kg of desipramine) and different strains of mice
(BALB/c versus Albino Swiss).
As demonstrated in the present study, caffeine augmented
the activity of the SSRI agents, which is a group of drugs that
are currently the first choice in the treatment of depressive
disorders. They are characterized by a safer profile of adverse
reactions compared with other antidepressants, and conse-
quently, they are better tolerated by patients. The recorded
synergy can also be explained by the inhibitory effect of caf-
feine on the effects of endogenous adenosine, which decreases
the release ofmany neurotransmitters in the CNS, including 5-
HT (Mössner et al. 2000). This blockage leads to an increase
in the amount of 5-HT in the synapse and modulation of the
serotoninergic transmission. Our observations are consistent
with the previous reports on this subject. For example, it was
shown that the administration of caffeine in the diet of rats
causes an increase in the concentration of 5-HT, 5-
hydroxyindoleacetic acid (a breakdown product of 5-HT),
and tryptophan (the starting material for the production of 5-
HT) in the CNS (Yokogoshi et al. 1987). A similar effect was
observed in rats after the administration of caffeine i.p. at
doses of 10–100 mg/kg (Fernstrom et al. 1984; Haleem et al.
1995). In vitro studies have also shown increased levels of 5-
HT in biological material (brain stem, brain, and cerebellum)
collected from rats after administration of caffeine (Berkowitz
and Spector 1971; Stromberg and Waldeck 1973).
As previously mentioned, caffeine is supposed to enhance
a release of NA in the CNS (Williams 1987). However, the
research involving methylxanthines (including caffeine)
showed conflicting results in terms of their impact on the level
of catecholamines. On the one hand, it has been demonstrated
that methylxanthines do not affect the concentration of NA in
the CNS of rats (Karasawa et al. 1976; Schlosberg 1984); on
the other hand, it has been reported that they stimulate the
metabolism and the release of catecholamines in the brain
(Atkinson and Enslen 1976; Costill et al. 1978). The enhance-
ment of anti-immobility action of reboxetine by caffeine co-
administration observed in our study is probably related to an
increased amount of NA in the CNS. As mentioned before,
reboxetine blocks neuronal reuptake of NA and the level of
this neurotransmitter rises in the CNS. Caffeine, due to antag-
onism of adenosine receptors, also increases the release of
NA, which has been observed in preclinical studies and clin-
ical trials; after administration of single doses of caffeine, in-
creased levels of NA were observed in blood and urine in
humans (Benowitz 1990; Papadelis et al. 2003) and in blood
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and brains of laboratory animals (Bender and Bobrova 1982;
Goldberg et al. 1982).
Hydrophobic properties of caffeine allow its easy penetra-
tion through all biological membranes. It is distributed to all
body fluids—plasma, cerebrospinal fluid, saliva, bile, semen,
milk, umbilical cord blood, and organ tissues (Arnaud 2011).
Almost all of caffeine is present in a pharmacologically active
form, since the fraction bound to plasma proteins is relatively
small (McCall et al. 1982). Pharmacokinetic studies carried
out in the present research were aimed at assessing concentra-
tions of antidepressants in blood and brain of mice after their
combined administration with caffeine and estimating the na-
ture of the agent-agent interactions. The present work is also
the first in which such an attempt was made. The existing data
on changes in the therapeutic effect of antidepressants caused
by concomitant administration of caffeine were based solely
on the results obtained in behavioral tests (Kale and Addepalli
2014; Robles-Molina et al. 2012). The available literature em-
phasizes the role of CYP1A2, the main enzyme responsible
for the metabolism of caffeine, in the metabolism of drugs
from different therapeutic groups, including antidepressants
(e.g., imipramine, mianserin, amitriptyline, or fluvoxamine).
Clinically significant pharmacokinetic interactions between
caffeine and these substances is related to the amount and
activity of this isoenzyme (Lin and Lu 1998; Pelkonen et al.
1998). We found that caffeine does not affect the concentra-
tions of most of the tested antidepressants (desipramine, flu-
oxetine, escitalopram, reboxetine) either in serum or brain
tissue. These results suggest that interactions observed be-
tween caffeine and these drugs presumably are pharmacody-
namic, which refers to changes at the cellular level. We report-
ed a statistically significant reduction in the amount of imip-
ramine in brain tissue, with no statistically significant changes
in serum drug concentration after a concurrent administration
with caffeine. It is possible that the observed alterations were
associated with the modifications in the biotransformation of
imipramine, since both caffeine and imipramine are metabo-
lized by the same isoenzyme of cytochrome P450 (Carrillo
and Benitez 2000) or imipramine transport through blood-
brain barrier. The interplay between caffeine and paroxetine
demonstrated in the course of our study is not entirely clear.
As a result of the joint administration of these agents, there has
been an increase in the serum concentration of paroxetine, but
concentration changes in the brain, which is the target site of
action of antidepressants, have not been observed. In the case
of drugs acting on the CNS, the concentration of drug in the
brain structures is responsible for the pharmacological effect.
However, the question of the correlation between the drug
concentration in blood and CNS is controversial. It is believed
that changes in the serum level should reflect changes occur-
ring in the amount of drug in the brain tissue. No such rela-
tionship may be due to the delay in the transport of the drug
through the blood-brain barrier (Burke and Preskorn 2004).
Accordingly, it can be concluded that the interaction between
caffeine and paroxetine takes place in the pharmacokinetic
phase. Both observed pharmacokinetic interactions could
have important consequences for patients that are coffee
drinkers or otherwise caffeine users under imipramine or par-
oxetine therapy.
Conclusions
In summary, we confirmed that caffeine produced an
antidepressant-like effect and demonstrated a caffeine-
induced enhancement of the antidepressant effect of imipra-
mine, desipramine, fluoxetine, paroxetine, escitalopram, and
reboxetine in the Porsolt’s test without stimulation of locomo-
tor activity. The interplay between the tested methylxanthine
and desipramine, fluoxetine, escitalopram, and reboxetine
seems to be exclusively pharmacodynamic in nature, whereas
an increased antidepressant activity of paroxetine or imipra-
mine was at least partly related to their pharmacokinetic inter-
action with caffeine. However, when formulating conclusions
concerning the type of the observed interactions on the basis
of the pharmacokinetic studies, one should be particularly
careful, since biotransformation of drugs may proceed differ-
ently in animals and humans.
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